Industry Weekly, the State Health Insurance Administration issued a paper to control pharmaceutical rebates;

Joint release: Sina Pharmaceuticals, Saidi consultants a week overview of policies and regulations, the National Health Insurance Administration on September 16 issued the "National Health Insurance Administration on the establishment of pharmaceutical prices and credit evaluation system guidance", requiring all regions by the end of 2020 to establish and implement the pharmaceutical price and credit evaluation system; Case acceptance number approval dynamics, 13 consistent evaluation acceptance number, investment and financing, a total of 11 investment and financing incidents in the field of domestic medical and health, disclosed financing amount of 1,993 million yuan, a total of 7 key investment and financing incidents in the field of foreign medicine and health, disclosed the total amount of financing of 275 million U.S. dollars ... The pharmaceutical and health industry this week inventory, wonderful continue! A total of three policy documents were released this week.
specific information is as follows.
, the National Health Insurance Administration on the establishment of medical prices and credit evaluation system guidance is the focus of this week's policy. Table
1 List of policy documents released this week Data sources: relevant departments, Seddy consultants to compile the focus of analysis issued by the National Health Insurance Administration "guidance on the establishment of pharmaceutical prices and credit evaluation system" (hereinafter referred to as "Opinion"), requiring all regions by the end of 2020 to establish and implement pharmaceutical prices and credit evaluation system.
The Opinions focus on the outstanding problems such as inflated prices of medicines and medical supplies caused by kickbacks in the pharmaceutical field, excessive growth of medical expenses, large loss of medical insurance funds, increasing the burden of medical expenses of the masses and infringing on the vital interests of the masses, exerting the guiding and normative role of the centralized procurement market for pharmaceutical products, promoting pharmaceutical enterprises to set prices in accordance with the principles of fairness, reasonable and honest credit, and consistent quality prices, and promoting the reasonable return of pharmaceutical products prices.
six guidances given in the Opinion, one is the directory list.
to the scope of evaluation of acts contrary to good-will, such as rebates.
is the commitment of enterprises.
pharmaceutical companies that participate in the centralized procurement of pharmaceuticals and medical supplies to make a committed commitment.
third is information recording.
to take a combination of enterprise reporting and platform records to grasp the information of pharmaceutical enterprises' loss of trust.
fourth is the credit rating.
the facts of the case determined by the court's judgment or administrative punishment, determine the level of loss of trust and update it dynamically.
is graded disposal.
measures such as warning, warning risk, restricting or suspending bidding, public disclosure of information of loss of trust, etc.
saturday is credit repair.
encourage enterprises to rectify, take practical measures to take the initiative to repair credit.
172 new cases this week in the registration and declaration of new drugs for research and development.
from the drug category, the largest number of chemical drug registration and declaration acceptance, 142 cases, accounting for 83%;
from the registered declaration type, 130 cases were supplementary applications, accounting for 76%, new drugs accounted for 9%, imitation acceptance accounted for 4%, import acceptance accounted for 3%.
from the point of view of the declared enterprises, this week's largest number of enterprises for Guangzhou Baitt Medical Supplies Co., Ltd., the number of cases accepted is 32, followed by ALFASIGMA S.p.A., the number of accepted 5 cases.
Figure 1 This week the national acceptance of registered drug category data source: Seddy Consultants Pharmaceutical Health Industry Brain Map 2 This week national acceptance of drug registration declaration type data sources: Seddy Consultants Pharmaceutical Health Industry Brain Map 3 This week the number of national enterprises to declare drug registrations TOP5 data sources: Seddy Consultants Pharmaceutical Health Industry Brain Consistency Evaluation, this week there are 13 acceptance numbers have the latest progress.
From the product point of view, mainly involved in injection of sodium diazepam, erythromycin tablets, methylcobalamin capsules, injection of omeprazole sodium, hydrochloric acid amino glucose tablets, sodium Ibanzyrate injection, methazole tablets, pyridine hydrochloride tablets, permain and other 9 varieties.
from the applicant enterprises, Shandong Green Leaf Pharmaceutical Co., Ltd. has the largest number of applications, the number of 3 cases.
Table 2 This Week's List of Consistent Evaluation Application Numbers Data Source: Seddy Consultants Medical Health Industry Brain Consistency Evaluation, 13 receiving numbers this week have the latest developments.
From the product point of view, mainly involved in injection of sodium diazepam, erythromycin tablets, methylcobalamin capsules, injection of omeprazole sodium, hydrochloric acid amino glucose tablets, sodium Ibanzyrate injection, methazole tablets, pyridine hydrochloride tablets, permain and other 9 varieties.
from the applicant enterprises, Shandong Green Leaf Pharmaceutical Co., Ltd. has the largest number of applications, the number of 3 cases. Form
2 This week's consistent evaluation application number list data source: Saidi consultant pharmaceutical health industry brain investment and financing wind to the domestic investment and financing market, this week in the field of pharmaceutical and health a total of 11 investment and financing incidents, disclosed financing amount of 1,993 million yuan.
The investment targets are Shifu Medical, Qingpu Bio, Yunkai Yamei, Bai osaitu, Jingfeng Medical, Oppen Medical, Tianchen Medical, Jingyu Shares, Tagier Bio, Kerry Corning and Runde Education, mainly related to pharmaceutical manufacturing, medical equipment, smart medical, vocational training and research and development of new drugs and other fields.
the amount disclosed, Bai osaitu has the highest amount of financing, amounting to 970 million yuan. Table
4 Data sources for this week's domestic investment and financing events: Saidi Consultants Medical and Health Industry Brain Focus Analysis Bai Osaitu is a high-tech biopharmaceutical enterprise based on stable and efficient gene editing technology platform, model animal customization services, important model animal development and large-scale reproduction and supply, in vivo pharmacological evaluation services, antibody drug research and development outsourcing services.
August 31, 2020, Beyo Saitu has just announced the merger of pythons and pharmaceuticals.
Shanghai Jingxuan Technology Co., Ltd. is the leading intelligent medical technology and service providers in China, covering mobile medical, hospital HLP, medical Internet of Things, nursing education, HCRM, cloud HIS, card, medical cloud and many other fields, the comprehensive layout of medical cloud, digital hospitals, regional smart medical.
Shanghai Jingxuan Technology Co., Ltd. has successfully provided technology, products and services to more than 3000 medical institutions of all types in China, including more than 700 third-level hospitals, to help medical institutions improve service quality and efficiency and ensure medical safety.
overseas investment and financing markets, there were seven key investment and financing events in the healthcare sector this week, with a total of $275 million disclosed, targeting Hexagon Bio, Volansi, Polyneuron, Coremap, Graphite Bio, Lava Therapeutics, RapidAI, and other sectors, mainly in the areas of pharmaceutical research and development, biopharmaceuticals, and smart healthcare.
, Lava Therapeutics received $82 million in financing, the highest amount.
Table 5 Overseas Investment and Financing Events Data Source: Seddy Consultants Medical Health Industry Brain Focus Analysis Hexagon Bio is a data-driven biotech company dedicated to developing targeted small molecule therapies.
Hexagon Bio's proprietary platform combines data science with synthetic biology to discover and design drugs from DNA sequences.
Hexagon Bio is digging into the fungal genome to find inspiration for the next generation of targeted therapies for diseases that do not meet their needs.
LAVA Therapeutics is developing a proprietary dual-specific antibody platform that binds to γ-t cells for the treatment of hematology and solid cancer.
company's best-in-class immuno-oncology method activates V-9V-2T cells when combined with membrane-expressed tumor targets.
LAVA was established in 2016 on the basis of intellectual property at the University of Amsterdam Medical Centre.
.